Top Page
Proteomics International Laboratories Ltd.
(Sydney:PIQ)
Proteomics International Laboratories Ltd. (PIQ) vs. iShares MSCI Australia ETF (EWA)
Proteomics International Laboratories Ltd. Business Overview & Revenue Model
Proteomics International Laboratories Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.50M | 960.39K | 892.14K | 730.34K | 1.49M | 1.31M |
| Gross Profit | 1.46M | 960.39K | -1.12M | -1.62M | -568.62K | 497.08K |
| EBITDA | -6.74M | -10.00M | -8.40M | -7.55M | -4.56M | -2.77M |
| Net Income | -7.11M | -8.11M | -6.38M | -6.23M | -4.97M | -2.86M |
Balance Sheet | ||||||
| Total Assets | 7.02M | 14.78M | 10.88M | 10.08M | 5.40M | 8.60M |
| Cash, Cash Equivalents and Short-Term Investments | 5.33M | 11.04M | 6.64M | 6.03M | 2.11M | 5.60M |
| Total Debt | 247.67K | 277.74K | 316.39K | 64.09K | 0.00 | 69.05K |
| Total Liabilities | 1.74M | 1.81M | 1.63M | 1.75M | 2.00M | 990.19K |
| Stockholders Equity | 5.46M | 13.17M | 9.41M | 8.38M | 3.39M | 7.61M |
Cash Flow | ||||||
| Free Cash Flow | -5.51M | -6.63M | -6.00M | -6.91M | -3.67M | -2.41M |
| Operating Cash Flow | -5.46M | -6.60M | -5.59M | -5.69M | -3.54M | -2.21M |
| Investing Cash Flow | -46.19K | -29.65K | -388.02K | -1.17M | -129.46K | -191.00K |
| Financing Cash Flow | 5.87M | 11.03M | 6.59M | 10.77M | 176.10K | 5.64M |
Proteomics International Laboratories Ltd. Technical Analysis
Proteomics International Laboratories Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$107.33M | -10.10 | -71.87% | ― | 7.65% | -19.13% | |
55 Neutral | AU$81.52M | -1.29 | -100.67% | ― | 1114.27% | 85.66% | |
52 Neutral | AU$189.42M | -7.16 | ― | ― | ― | 0.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$84.12M | -8.35 | -49.72% | ― | ― | 10.78% | |
45 Neutral | AU$11.05M | ― | -469.35% | ― | ― | 46.28% | |
44 Neutral | AU$76.31M | -2.66 | -247.98% | ― | ― | ― |
Proteomics International Laboratories Ltd. Corporate Events
Proteomics International Laboratories Ltd has applied to the ASX for quotation of 1,164,320 new ordinary fully paid shares, to be issued on 21 January 2026 under its ticker PIQ. The additional securities, arising from the exercise or conversion of existing instruments, modestly expand the company’s quoted capital base, potentially enhancing liquidity for shareholders and supporting ongoing corporate and operational funding needs.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.74 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has appointed David Morris as a director effective 19 January 2026, according to an initial director’s interest notice lodged with the ASX. The filing confirms that Morris currently holds no relevant interests in the company’s securities and has no disclosed interests in related contracts, indicating a board-level change without immediate implications for the company’s capital structure or ownership dynamics.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.74 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories has secured a Canadian patent for PromarkerEso, its first-in-class blood test designed for the early diagnosis of esophageal adenocarcinoma, extending intellectual property protection for the test in Canada until November 2035. The patent strengthens the company’s commercialisation pathway in North America by supporting potential direct sales, partnerships and licensing, and complements existing protection in Australia, China, Hong Kong, Europe and the US. Given that esophageal adenocarcinoma is frequently linked to chronic acid reflux, has poor survival rates and is often diagnosed late due to reliance on invasive and costly endoscopy, the company positions PromarkerEso as a highly accurate, less invasive screening tool that could meet a significant unmet clinical need and support its growth in global diagnostics markets.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.84 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has applied to the ASX for quotation of 147,286 new fully paid ordinary shares under its ticker PIQ, effective 16 January 2026. The incremental issuance modestly expands the company’s listed share capital, potentially enhancing liquidity in its stock and reflecting ongoing exercise or conversion of existing securities by investors.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.84 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories has appointed David Morris as Chief Executive Officer and Managing Director, effective 19 January 2026, marking a leadership transition from founder Dr Richard Lipscombe, who retires after 25 years but will assist during a handover period. Morris, a seasoned healthcare and medtech executive with experience at Cochlear, Nanosonics, Polynovo and Monash IVF, is being brought in to drive commercial execution and international market penetration of the company’s Promarker diagnostic pipeline, with a remuneration package heavily weighted to performance-based short- and long-term incentives, underscoring the board’s focus on translating its precision diagnostic technology into global commercial growth for patients and shareholders.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.63 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has lodged an application with the ASX for quotation of 32,430 new ordinary fully paid shares under the code PIQ. The additional securities arise from the exercise or conversion of existing options or other convertible securities, slightly increasing the company’s quoted share capital and potentially broadening its investor base, though the modest size of the issue suggests minimal immediate dilution for existing shareholders.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.63 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has notified the market that 15,072 employee performance rights (ASX code: PIQAY) have lapsed as of 31 December 2025 because the conditions attached to those rights were not met or became incapable of being satisfied. The cessation modestly reduces the company’s potential future issued capital under its employee incentive arrangements but does not involve any new capital raising or change to existing listed securities, indicating a routine adjustment to its share-based remuneration structure.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.63 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories has strengthened its US footprint after its Irvine, California reference laboratory secured accreditation from the College of American Pathologists, a quality benchmark regarded as the gold standard and more demanding than existing CLIA certification. Alongside the accreditation, the company has commissioned a new mass spectrometry platform to support commercialisation of its Promarker suite of precision diagnostic blood tests, initially focusing on establishing the PromarkerEso assay for esophageal adenocarcinoma ahead of a planned US launch in 2026, while also positioning the facility to run future tests such as PromarkerEndo for endometriosis, reinforcing Proteomics International’s positioning as a leading provider of high-quality precision diagnostics.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the publication of a peer-reviewed study in the Internal Medicine Journal, demonstrating the clinical utility of their PromarkerD test in Australia. The study showed that PromarkerD significantly influences clinical decision-making by prompting earlier initiation of renoprotective therapies and reducing the use of nephrotoxic drugs among patients at risk of diabetic kidney disease. With 89% of surveyed physicians believing in the test’s potential to improve clinical outcomes, the findings support PromarkerD’s role in enhancing treatment strategies for the 1.5 million Australians with type 2 diabetes, potentially leading to better patient management and reduced healthcare costs.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the commercial launch of its precision diagnostics services, marking a significant milestone in the company’s operations. This move is expected to enhance the company’s market positioning in the healthcare sector, potentially offering new opportunities for growth and development, and providing stakeholders with insights into the company’s future trajectory.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd responded to an ASX price query, clarifying that recent trading activity in its securities is likely due to several significant announcements. These include the US Medicare setting a reimbursement price for their PromarkerD test, which supports their US launch strategy, and new data on their OxiDx test indicating its potential to improve racehorse performance. The company has also achieved milestones such as clinical certification for its Australian diagnostics laboratory and initial sales of PromarkerD and PromarkerEso in Australia. These developments have likely contributed to increased investor interest.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.38 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced that the US Centers for Medicare & Medicaid Services (CMS) has set a reimbursement price for their PromarkerD test, a predictive diagnostic for diabetic kidney disease, at $390.75. This decision is a significant milestone for the company, enhancing their US launch strategy by facilitating broader patient access and strengthening discussions with private payers. The PromarkerD test, which can predict diabetic kidney disease up to four years before symptoms appear, has the potential to improve care for over 32 million adults in the US with diabetes, reduce healthcare costs, and drive adoption and commercial partnerships.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the quotation of 50,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code PIQ. This move is part of the company’s ongoing efforts to enhance its market presence and provide additional value to its stakeholders by leveraging its expertise in proteomics.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the issuance of new unquoted equity securities, specifically options expiring in 2028 and 2029. This move may impact the company’s financial strategy and provide additional resources for its ongoing projects, potentially strengthening its position in the biotechnology sector.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced a change in the director’s interest, specifically regarding Neville Gardiner’s indirect holdings. The announcement detailed the expiration of 250,000 unquoted options that were not exercised, impacting the director’s indirect interest holdings. This change reflects the company’s ongoing management of its securities and may influence stakeholder perceptions of the company’s governance practices.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the cessation of 375,000 securities under the ASX code PIQAZ, which expired on November 24, 2025, without being exercised or converted. This announcement may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s financial strategies and market positioning.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced that all resolutions at their Annual General Meeting were passed by poll. This outcome reflects strong shareholder support and may positively influence the company’s strategic initiatives and governance, potentially enhancing its position in the medical technology sector.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced at its Annual General Meeting that Richard, the founding Managing Director, will retire in early 2026 after 25 years with the company. The recruitment process for his successor is well underway, ensuring a smooth leadership transition. The company acknowledged Richard’s significant contributions and the promising future opportunities for Proteomics International.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced its participation in the Bell Potter Healthcare Conference 2025, where Dr. Richard Lipscombe will present on the company’s advancements. This engagement underscores the company’s commitment to showcasing its innovative diagnostic solutions, potentially enhancing its industry position and stakeholder engagement.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has bolstered its cash reserves with a $2.2 million R&D tax incentive for the 2024-25 financial year. This funding supports the commercialization of their diagnostic tests, including Promarker®D for Diabetic Kidney Disease and Promarker®Endo for Endometriosis, as well as their ongoing R&D efforts. The rebate, part of the Australian Government’s initiative to encourage beneficial research, highlights the company’s commitment to advancing its diagnostic pipeline and strengthening its market position.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has received a $500,000 grant from the Western Australian Government to support the commercialization of PromarkerEndo, a pioneering blood test for diagnosing endometriosis. This funding will aid in regulatory, marketing, and partnership efforts, addressing the global health challenge of endometriosis, which affects one in nine women. The test offers a non-invasive alternative to current diagnostic methods, potentially transforming women’s healthcare by reducing the average seven-year diagnosis time, and is expected to launch in Australia in the second half of 2025.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.